Crispr 101: Your Guide To Understanding CRISPR
Crispr 101: Your Guide To Understanding CRISPR
Crispr 101: Your Guide To Understanding CRISPR
Read on for a crash course in everything you need to know about the
fundamentals of CRISPR.
History of CRISPR
The foundational discoveries that led to the development of CRISPR-
Cas9 technology can be traced back to 1993, when repetitive palindromic
segments of DNA interspaced with other fragments of genetic material
were identified in prokaryotes. These pieces of genetic code were named
Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR.
How does the Cas9 protein recognize the target DNA? It is directed to the
target sequence by a short RNA fragment known as a guide RNA (gRNA).
The guide RNA is complementary to a segment of the viral genome,
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats. A set of DNA
which allows Cas9 to cleave DNA with a high degree of specificity.
sequences involved in the prokaryotic immune system and has been adapted for
genome engineering.
Not only does that destroy the virus, but the fragment of foreign DNA,
called a "spacer," may be stored between the palindromic sequences
of the CRISPR array as a way of retaining a genetic memory of past Once scientists figured out the mechanism of CRISPR in prokaryotes, it
infections. If the virus were to re-invade, the CRISPR-Cas9 system could did not take long for them to realize the potential for engineering the
quickly target and destroy it. This library of viral fragments is thus genomes of microbes, plants, and animals. Today, CRISPR is utilized
essentially equivalent to our immune system, which stores antigens to for a variety of applications and its adoption continues to increase in
prepare for future infections. laboratories throughout the world.
5' 3'
N
CC
The Cas9 protein functions as a pair of molecular scissors, while the 3' 5'
G
G
N
Target DNA PAM
gRNA is the GPS that guides it to the appropriate site. In bacteria, the
gRNA guides nuclease to viral DNA, but as a biotechnological tool, the
design specifications of the gRNA can be altered to target the nuclease to
cleave any host organism’s genome at virtually any location.
that Cas9 does not cleave its own CRISPR locus. The PAM sequence varies
for Cas9 proteins from different species: the PAM for the most widely sequences complementary to viral DNA. When used for gene editing,
used Cas9 from Streptococcus pyogenes is 5′-NGG-3′, where N is any however, the crRNA can be programmed to target virtually any genetic
nucleotide. sequence. The tracrRNA functions as a scaffold for the crRNA-Cas9
interaction. Guide RNAs naturally form a duplex molecule, with the
In its natural form, the gRNA consists of two distinct segments of crRNA and tracrRNA segments annealed together (crRNA:tracrRNA).
RNA: CRISPR RNA (crRNA) and transactivating CRISPR RNA (tracrRNA). Synthetically, they can be engineered as one seamless fusion sequence
The crRNA is complementary to the target DNA sequence, and thus called a single guide RNA (sgRNA) (Fig 2).
recognizes the sequence to be cleaved. In nature, the RNA consists of
Guide RNA (gRNA): the RNA component of the CRISPR- CRISPR-associated endonuclease protein (Cas9): PAM (protospacer adjacent motif): a short sequence of
Cas9 genome engineering tool. Contains a guide sequence a common endonuclease used in the CRISPR-Cas9 genome nucleotides that must be present downstream of the target
that is complimentary to the genomic target. engineering tool. Makes a double strand break on the DNA site in order for the nuclease to make a double strand
` at the targeted genomic region. break.
3' 5'
5' 3'
Cas9 3' 5'
Insertion
DSB
OR
sgRNA 5' 3'
3' 5' 5' 3'
Homology Arms
Figure 2. CRISPR-Cas9 genome editing. 1) The components of CRISPR are a guide RNA (either sgRNA or 5' 3'
Donor DNA
cr:tracr) and a Cas9 endonuclease. 2) The guide RNA and Cas9 form a ribonucleoprotein (RNP). 3) Inside Template
3' 5'
the cell, the RNP creates a double-strand break (DSB) at the genomic target. One of two endogenous
Knock-In Sequence
repair mechanisms may mend the break. 4a) Non-homologous end joining (NHEJ) repair) is error-prone
pathway that often inserts or deletes nucleotides (indels). If an indel causes a frameshift mutation, then
the target gene may lose function (knockout). 4b) If a DNA template is provided, then the homology-
directed repair (HDR) pathway may mend the break through homologous recombination. This pathway 5' 3'
Knock-In Sequence
The magic of CRISPR is in its ability to cleave both strands of DNA. Cells
must repair DSBs, or risk dying. Thus, all of the editing that comes from
CRISPR is due to the cell’s innate ability to repair itself. There are two 5' 3'
kinds of repair pathways, each of which can be exploited to make desired 3' 5'
Insertion
edits.
OR
no functional protein is made (knockout), then one can exploit the cell’s
non-homologous end joining (NHEJ) repair mechanism. NHEJ binds the Figure 3. Non-homologous end joining repair (NHEJ): an error-
prone cellular mechanism that repairs double strand breaks in DNA,
double stranded break back together, but it is prone to error and may but often inserts or deletes nucleotides (indels) in the process. Can
insert or delete nucleotides (called indels) in the process. If the number be used to induce knockouts.
Homology-Directed Repair
Alternatively, if the objective of the experiment is to replace the targeted Homology arms
genetic element with a different sequence (e.g., knock-in), the cell can Repair
5' 3'
template
be directed towards an alternative repair pathway, homology-directed 3' 5'
Knockin sequence
CRISPRi
Gene
Knock-in
Silencing
Knock-ins the gene, thereby silencing its expression. Fusing a transcriptional repressor
protein to dCas9 allows reversible and fine-tuned reduction in gene
The incorporation of genetic material into a cell’s genome is referred to as expression.
Knockout (KO): a mutation in a genetic sequence that Knock-in (KI): the integration of a foreign genetic CRISPRi: a gene-silencing technique whereby a gRNA
causes it to be inoperative (i.e., no functional protein is sequence into a cell’s genome. binds to a target and an associated dead Cas9 blocks
made). transcription machinery from accessing the DNA..
In a nod to the precursor gene-silencing technique, RNA interference Neisseria meningitidis (Nme). In fact, the team showed inhibition of the
(RNAi), the CRISPR silencing technique has been termed CRISPR Nme-Cas9 activity and binding in bacterial and mammalian cells using
interference, or CRISPRi (3). Compared to RNAi, CRISPRi is associated these anti-CRISPR proteins (6). Ultimately, this technology can be used to
with higher efficiency, greater versatility, and fewer off-target effects. reduce editing errors. It turns out that adding anti-CRISPR proteins after
editing takes place only partially reduces cleavage at on-target sites, but
While dCas9 endonucleases can be used to silence gene expression, CRISPR Screens
they can also be further modified to enable fine-tuned control over
the activation of target genes (called CRISPR activation or CRISPRa). By Another application of CRISPR technology is in genome-wide functional
fusing a transcriptional activator to dCas9, scientists are now developing screening. Until recently, RNAi was the primary approach for performing
systems that can overexpress genes of interest. Polstein and Gersbach such screens, whereby genes are systematically inhibited across the
created one such system by fusing light-inducible proteins to mutated genome in order to determine their associated function and phenotype.
Cas9, causing gene expression to be activated in the presence of blue However, as mentioned previously, RNAi is plagued with problems
light and repressed in its absence (4). Other teams of researchers, such related to low efficiency and high off-target effects. With the advent
as Zalatan et al., are building more complex systems for multiplexed of CRISPR, genomic screening libraries are now being developed and
gene activation and repression at as many as three loci simultaneously applied to knockout thousands of genes in a single screen with high
(5). efficiency. Schmidt and colleagues recently developed a CRISPR screening
library based on HEK293T cells that targets nearly every known protein-
Anti-CRISPR coding gene in the human genome and that they are making freely
available to the research community (7).
Although the CRISPR-Cas9 system enables fine-tuning of genomic DNA,
one downside is the risk of off-target effects (cutting DNA in the wrong Gene Visualization
place). One solution to this issue is to harness “anti-CRISPR” proteins that
inhibit Cas9 activity. In nature, phages use these proteins to evade the The CRISPR system can also be used to visualize genomic regions. This is
CRISPR machinery of the bacteria. Recently, Pawluk et al. discovered anti- achieved by attaching fluorescent proteins (like GFP) to dCas9 proteins
CRISPR protein inhibitors that were effective against Cas9 nuclease from and using the CRISPR system to tag desired parts of the genome. (8,9).
CRISPRa: a gene-activation technique whereby a transcriptional activator is complexed with anti -CRISPR: proteins that prevent Cas9 from cutting DNA. Anti-CRISPR can be used to
dCas9 to increase the expression of a gene of interest. reduce off-target effects while maintaining on-target activity.
Multi-guide Multi-guide sgRNAs: multiple gRNAs designed to target the same gene and are introduced
to cells simultaneously.
Scientists can introduce multiple gRNAs that target the same gene (multi-
guide) into cells at once. This method has been shown to induce large
fragment deletions that can efficiently knock out genes. Alternatively,
gRNAs can be used to edit several genes simultaneously (10,11).
Design
The first step of a CRISPR experiment involves designing gRNAs and
choosing an appropriate Cas9 nuclease.
Edit
The gRNAs and Cas9 are delivered to cells so that genome editing can
take place. The format of the CRISPR components and method of delivery
into cells are important factors in this step.
Analyze
After CRISPR editing, the targeted genomic sequences must be analyzed
to assess the frequency and type of edits made. Obtaining high
frequencies of the desired edit is highly dependent on the design and
edit steps of the workflow.
Choosing the Right CRISPR For knock-in, CRISPRa, and CRISPRi experiments, gRNAs have additional
requirements. For knock-in experiments, the template DNA should be
Components carefully checked for PAM sequences to ensure that it is not treated as
a target. For CRISPRa/ CRISPRi applications, the gRNA sequence should
The design of gRNA and choice of the nuclease be complementary to the promoter regulating the target gene, rather to
depends on the desired application. The right choice of sequence of the gene itself.
components is crucial for a successful experiment.
Design Tools
Designing the Guide RNA Several online tools are available to help design guide RNAs by predicting
their on-target and off-target activity. We have listed some of these
The guide RNA is the programmable component of the CRISPR-Cas9
below.
system that directs the Cas9 nuclease to the target site. Therefore, it is
important to ensure that the guide sequence yields minimum off-target
Synthego CRISPR Design Tool
(unintended) cuts while also providing maximum on-target activity.
Synthego’s free CRISPR design tool is one of the fastest and most efficient design tools
available for researchers. The tool offers easy design of synthetic sgRNAs with up to
Stringency of additional parameters for RNA sequence design further 97% editing efficiency and the lowest off-target effects. It includes a library of more
than 100,000 genomes and 9,000 species, and offers a convenient way to order your
varies with the intended applications. For instance, knock out procedures
guides within the tool. You can also use the tool to validate gRNAs designed using
rely on cells forming frameshifts in the DNA during repair of the DSB by other platforms.
NHEJ. The faulty reading frame disrupts transcription of the gene, and
thereby downstream protein coding. These experiments offer some MIT CRISPR Designer
flexibility in terms of sequence selection and target location of the guide The MIT CRISPR designer is another free platform that helps users design gRNAs with
high target selectivity and low off-target effects.
RNA. Nevertheless, the following criteria should be met when designing
guide RNAs for KO experiments:
sgRNA Scorer 2.0
The sgRNA scorer 2.0 from the Dr. George Church’s lab identifies target sites for gRNA
• Choose guide sequences that target exons that are present in all from an input DNA sequence. The tool currently allows selection from six different
nucleases, and predicts the activity of Cas9 nucleases derived from S. aureus and S.
transcript variants. thermophilus 3 especially well.
• Choose sequences at the 5’ end of the gene or that encode essential Benchling
protein domains, as these are more likely to interfere with protein Benchling’s cutting edge design tool conveniently integrates other tools so that
scientists can use a single interface for designing their experiment. While the basic
function. plan is free, users need to pay fees for accessing their Startup and Enterprise plans.
Selecting a Nuclease
Several types of nucleases are now available for CRISPR applications. Selecting one depends on the specific goals and
limitations of the experiment. The four nucleases described below facilitate many types of genome editing projects. As
additional nucleases are discovered, we can expect CRISPR editing to become even more flexible and more powerful
than it is today.
of Cas9 within the cells. Plasmids also run the risk of integrating into
Different Formats of CRISPR Guides
A CRISPR genome editing experiment can be
genome of the host cell in places that cause cytotoxicity. This is
orchestrated in several different ways. The essential
particularly problematic in applications related to human medicine and
CRISPR machinery (gRNA and Cas9 protein) can be crop engineering.
delivered in one of the three formats: plasmid DNA,
in vitro-transcribed RNA, or ribonucleoprotein (RNP) RNA
complex. The CRISPR components can be delivered into the cells in RNA format:
gRNA and RNA encoding the Cas9 protein. The RNA can be produced
DNA enzymatically through in vitro transcription (IVT) or through a synthetic
One approach is to deliver CRISPR components into the cells as plasmid process.
DNA. This approach requires a researcher to clone both the Cas9 protein
and desired gRNA DNA fragments into a plasmid, and then introducing In vitro transcription (IVT)
the plasmid into target cells. Commercial plug-and-play plasmids are The RNA can be enzymatically transcribed from the corresponding DNA
now available for this purpose, allowing researchers to insert a gRNA outside the cell in a process called in vitro transcription (IVT). The first
sequence with their design specifications. step is same as that in plasmid cloning: design the DNA template based
on the target sequence within the gene of interest. In this case, the
The first step involves designing the DNA template to encode the gRNA template must additionally include an upstream promoter site (typically
and Cas9 protein. Once the DNA template sequence has been designed, T7) for the RNA polymerase to use during transcription.
an oligo can be ordered and cloned into a plasmid. Engineering a CRISPR
plasmid follows the same protocol as a typical cloning assay. The DNA Once the DNA template has been obtained, it is then transcribed into a
template insert must be amplified, digested, and ligated with the plasmid gRNA using one of multiple IVT kits available on the market (containing
before being transformed into cells. After screening for the recombinant enzymes and reagents). The IVT process requires 1-3 days to prepare
plasmid and verifying its sequence, the plasmid can be delivered to the the gRNA for a CRISPR assay. After purification, the gRNA can be co-
target cell. transfected into the cell alongside Cas9 mRNA. Alternatively, it can
also be complexed with Cas9 protein and delivered to the target cell as
Overall, the process of preparing a custom CRISPR plasmid in-house ribonucleoproteins (RNPs).
consumes 1–2 weeks of time before the actual editing assay can be
undertaken. In addition to the excessive time investment, the plasmid The IVT approach is laborious and not scalable for multiple CRISPR
approach is also prone to off-target effects due to the continual presence targets. In addition, IVT-derived gRNAs are prone to mistakes made by
enzymes during synthesis. For instance, RNA polymerase may insert the be introduced with Cas9 protein as ribonucleoprotein complexes, as
wrong nucleotide, or make a guide sequence too long or short. This may described below.
not only lead to highly variable editing efficiencies but also increase the
possibility of off-target effects. Ribonucleoprotein (RNP)
Deploying gRNA with Cas9 protein as ribonucleoprotein (RNP) complexes
Synthetic guide RNA
is the most effective strategy, as researchers have demonstrated higher
A convenient substitute to the IVT-derived guide RNA involves synthetic editing efficiencies and fewer potential off-target effects using RNPs as
polymerization of high-quality RNA (up to 120-mer) sequences. These compared to other delivery methods (11). Moreover, as the RNP exists
can either be in the form of separate crRNA and tracrRNA fragments that transiently inside the cell (not inserted into the genome), there is low risk
must be annealed together, or as seamless single guide RNA (sgRNA). Of of cytotoxicity.
these two forms, sgRNA generally produces a higher editing efficiency
by avoiding the inefficient annealing of the two-piece system, and the It has become clear that the RNP format is the most effective option for
tendency of tracrRNA fragments to form tetramers that interfere with the carrying out CRISPR gene editing assays and other applications, especially
Cas9 protein. in embryos.
Until very recently, the cost associated with producing synthetic sgRNA
was high enough to make synthetic sgRNA a prohibitive expense for
many laboratories. However, recent developments in technology enable
affordable access and successful deployment of the CRISPR technology.
One such advancement lies in Synthego’s automated and scalable
production methods, which allows these sgRNAs to be generated
much more rapidly and at a much lower cost than traditional synthesis
methods. The high-throughput synthesis technique also results in higher
fidelity sgRNAs, as compared to IVT-derived guides, enabling more
Ribonucleoprotein (RNP): a complex guide RNA and Cas9 protein. A popular
efficient and reproducible targeting of the desired genomic site. transfection format for CRISPR editing.
Table 2. Comparison of cost, time, and labor associated with different guide RNA formats
FL E X I B I L I T Y
stem cells primary cells cell lines stem cells primary cells cell lines stem cells primary cells cell lines
PR E P A R A T I ON S TEP S 3 5 5
Lipofection Microinjection
In a lipid-based delivery system, cationic lipid reagents facilitate delivery
Microinjection is commonly used to inject the Cas9 and gRNA into
of biomolecules into cells. This method is high-throughput, has low
oocytes or zygotes in order to generate genetically engineered
cytotoxicity, and is applicable in various cell types. Traditionally used for
organisms. This technique can also be used to transfect some types of
delivering nucleic acids in cells, lipofection has recently been optimized
cells. Zebrafish, mouse, and human embryos have been manipulated
for delivering RNPs into cells.
using this technique.
Lipid complexed with genetic Electric pulse forms pores in An electroporation-based Microneedle injects CRISPR DNA/RNA is packaged into
material fuses with the cell the cell membrane for entry method that delivers materials components inside cells, infectious particles and
PR IN C I P L E
membrane. of DNA/RNA/RNP. directly to the nucleus pre- oocytes, or zygotes. introduced into cells.
optimized for each cell type.
• Cost effective • Easy, fast • Easy, fast • High efficiency • High efficiency
ADV A NTA G E S
• High throughput • High efficiency • High efficiency
Virus
Viral vectors can be used to transfer DNA or RNA into cells in a process
called transduction. There are several types of viruses that can be used
for transduction, including lentivirus, adenovirus, adeno-associated virus
(AAV), and herpes viruses. For stable transduction, lentiviruses, are often
used because they integrate their genome into the genome of infected
cells.
Scientists are now using a modified version of CRISPR to explore epigenomics—the genome-wide
set of chemical groups that adorn DNA and its associated histone packaging proteins. Previously,
researchers were merely able to catalogue the correlation between epigenetic markers and gene
expression in cells. Now, a CRISPR complex that is capable of acetylating histone proteins at precise
locations dictated by the complex’s gRNA has been developed (12). Such technologies can shed light
on the causal relationship between epigenetic markers and gene expression in the future.
CRISPR is also enabling the elucidation of large portions of the human genome, the function of Additional Information
the vast majority of which is unknown. Scientists have long been trying to identify the location For an up-to-date list of all Synthego Application
Notes and other resources, please visit
and function of ‘non-gene’ genetic elements that do not code for proteins but are thought to
Synthego.com/resources
have important regulatory roles in expression. CRISPR is allowing researchers to knock out these
For technical assistance,
previously uncharted regions to study their role in the cell (13). contact our Scientific Support Team
CRISPR is also playing an increasingly important role in the biomedical industry. The process of drug Ph: 888.611.6883
discovery is notoriously long, arduous, and expensive. CRISPR, however, is likely to expedite the Email: [email protected]
pre-clinical stage of developing new drugs. For instance, CRISPR screening libraries are now available
to facilitate the discovery new drug targets. CRISPR can also be used to develop accurate disease About Synthego
models to validate potential drugs. In parallel, research using CRISPR for in vivo and ex vivo therapies
Synthego is the leading genome engineering
is on the rise. There is a lot of excitement and optimism that that CRISPR will enable the development innovation company. The company’s automated,
of better therapies and more personalized medicine in the near future. full stack genome engineering platform enables
broader access to CRISPR to accelerate basic
scientific discovery, uncover cures for diseases,
CRISPR is not only paving the way for researchers to solve the most difficult of problems in the life and develop novel synthetic biology applications.
sciences, but it is also enabling the scientific community to explore dimensions of the genome that Headquartered in Silicon Valley, Synthego is used
by scientists from the largest global biotechnology
we’ve been unable to study up until this point. Due to its adaptability across a wide range of species
companies and global biology universities to unlock
and its simplicity of use, CRISPR-Cas9 has quickly revolutionized genome engineering. CRISPR-Cas9 the potential of gene editing.
technology promises to deliver some truly stunning advances within the coming decades, particularly
in relation to human therapeutics, agricultural biology, biofuels, and basic scientific research.
References
1. van Overbeek M, Capurso D, Carter MM, Thompson MS, Frias E, Russ 7. Schmidt T, Schmid-Burgk JL, Hornung V. Synthesis of an arrayed sgRNA
C, Reece-Hoyes JS, Nye C, Gradia S, Vidal B, Zheng J, Hoffman GR, Fuller library targeting the human genome. Sci Rep. 2015 Oct 8;5:14987. doi:
CK, May AP. DNA Repair Profiling Reveals Nonrandom Outcomes at 10.1038/srep14987. PubMed PMID: 26446710; PubMed Central PMCID:
Cas9-Mediated Breaks. Mol Cell. 2016 Aug 18;63(4):633-46. doi: 10.1016/j. PMC4597219.
molcel.2016.06.037. PubMed PMID: 27499295..
8. Ma, Hanhui, et al. Multicolor CRISPR labeling of chromosomal loci in
2. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, Yan Z, Li D, Li J. Correction human cells. Proceedings of the National Academy of Sciences 112.10
of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell. (2015): 3002-3007.
2013 Dec 5;13(6):659-62. doi: 10.1016/j.stem.2013.10.016. PubMed PMID:
24315440. 9. Ma, Hanhui, et al. Multiplexed labeling of genomic loci with dCas9 and
engineered sgRNAs using CRISPRainbow. Nature biotechnology 34.5
3. Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS. CRISPR (2016): 528.
interference (CRISPRi) for sequence-specific control of gene expression.
Nat Protoc. 2013 Nov;8(11):2180-96. doi: 10.1038/nprot.2013.132. PubMed 10. Cong, Le, et al. Multiplex genome engineering using CRISPR/Cas
PMID: 24136345; PubMed Central PMCID: PMC3922765. systems. Science 339.6121 (2013): 819-823.
4. Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system 11. Liang, Xiquan, et al. Rapid and highly efficient mammalian cell
for control of endogenous gene activation. Nat Chem Biol. 2015 engineering via Cas9 protein transfection. Journal of biotechnology 208
Mar;11(3):198-200. doi: 10.1038/nchembio.1753. PubMed PMID: 25664691; (2015): 44-53.
PubMed Central PMCID: PMC4412021.
12. Hilton IB, D’Ippolito AM, Vockley CM, Thakore PI, Crawford GE,
5. Zalatan JG, Lee ME, Almeida R, Gilbert LA, Whitehead EH, La Russa M, Reddy TE, Gersbach CA. Epigenome editing by a CRISPR-Cas9-based
Tsai JC, Weissman JS, Dueber JE, Qi LS, Lim WA. Engineering complex acetyltransferase activates genes from promoters and enhancers. Nat
synthetic transcriptional programs with CRISPR RNA scaffolds. Cell. Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. PubMed PMID:
2015 Jan 15;160(1-2):339-50. doi: 10.1016/j.cell.2014.11.052. PubMed PMID: 25849900; PubMed Central PMCID: PMC4430400.
25533786; PubMed Central PMCID: PMC4297522.
13. Ho TT, Zhou N, Huang J, Koirala P, Xu M, Fung R, Wu F, Mo YY. Targeting
6. Pawluk, April, et al. Naturally occurring off-switches for CRISPR-Cas9. Cell non-coding RNAs with the CRISPR/Cas9 system in human cell lines.
167.7 (2016): 1829-1838. Nucleic Acids Res. 2015 Feb 18;43(3):e17. doi: 10.1093/nar/gku1198.
PubMed PMID: 25414344; PubMed Central PMCID: PMC4330338.